was downgraded at UBS to Neutral from Buy. $35 price target. Limited margin upside in near to mid term, UBS said.
was upgraded at Goldman Sachs from Sell to Neutral. $18 price target. New engineered cabs business should boost earnings, Goldman said.
STOCK COMMENTS / EPS CHANGES
numbers were increased at Sterne Agee. Estimates were raised through 2013. Checks show that customer demand is becoming stronger, Sterne Agee said.
was added to US1 list at Bank of America/Merrill Lynch. Valuation call, based on a new $26 price target, BofA/Merrill said.
CSX numbers were lowered at Jefferies. Shares are now seen reaching $28. Estimates were also lowered on mild weather, Jefferies said. Buy rating.
numbers were boosted at Bank of America/Merrill Lynch. Estimates were also increased, as the company continues to operate in a sweet spot of the credit cycle. Buy rating.
numbers were raised at Credit Suisse. Shares are now seen reaching $69. Estimates were also raised on healthy book-to-bill and positive meetings with management, Credit Suisse said. Neutral rating.
numbers were reduced at Sterne Agee. Shares are now seen reaching $25. Estimates were also cut. Company is investing more on digital technologies, Sterne Agee said. Buy rating.
(GRPN - Get Report)
estimates, target cut at Benchmark. Shares are now seen reaching $28. Estimates were also reduced, given higher refund amounts, Benchmark said. Overweight rating.
price target was increased at Citigroup to $23. Divestitures are on track, but there is no plan to break up the pharma business, Citigroup said.
numbers were raised at Keybanc. Shares are now seen reaching $21. Estimates were also increased, as a cyclical spending recovery should continue to unfold over the coming quarters, Keybanc said.
estimates and target were raised at Bank of America/Merrill Lynch. Shares are now seen reaching $75. Estimates also increased, as the company is leveraged to higher global handset growth, BofA/Merrill said. Buy rating.
price target was raised to $70 at Williams Capital. Company is expanding with new products and locations, Williams said. Outperform rating.
estimates and target were lowered at Dahlman Rose. Estimates were cut through 2013. Company is seeing lower North American pressure pumping results, Dahlman Rose said. Buy rating and new $89 price target.